NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Suzhou SmartNuclide Biopharmaceutical Co., Ltd.

Suzhou SmartNuclide Biopharmaceutical Co., Ltd.

Private
SuzhouHealthcare & Life Scienceshttps://www.smartnucl.com/

Last Round

Series C

Extension

Apr 9, 2024

Total Funding Raised

$43.44M

Company Overview

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. is a biotechnology company that develops innovative diagnostic and therapeutic radiopharmaceuticals for oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Imaging, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

radiopharmaceuticalsradionuclide drug conjugateRDCnanobodyprecision oncologynuclear medicinerecombinant human thyroid stimulating hormonerhTSHtargeted therapydiagnostic imagingtheranosticsthyroid cancer treatmentbiopharmaceutical R&Ddrug developmentsolid tumor therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Comparables

Compare Suzhou SmartNuclide Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Suzhou Zelgen Biopharmaceuticals Co Ltd
82%
Sanofi
78%
Ablaze Pharmaceuticals
78%

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionApr 9, 2024
Series CJul 7, 2021
Series BApr 23, 2020
Series A ExtensionNov 1, 2018
Series AMar 22, 2018
Angel
Mar 1, 2016

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Investors

Notable investors and investment history

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. investors
InvestorRounds
Agricultural Bank of China InternationalSeries C
Longmen CapitalSeries A Extension
Oriza HoldingsSeries C Extension
Peppermint Venture PartnersAngel
Jiuyo Capital ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2024

    $14M round led by Oriza Holdings

  • Jul 7, 2021

    $15.5M round with Agricultural Bank of China International and CIB Guoxin.

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Suzhou SmartNuclide Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Suzhou SmartNuclide Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range6
Year Founded2015
Last FundingApr 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.